Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
Annals of hematology. - 100 (2021) , 1637–1640, ISSN: 1432-0584
- Event
-
Veröffentlichung
- (where)
-
Freiburg
- (who)
-
Universität
- (when)
-
2021
- Creator
- DOI
-
10.1007/s00277-021-04490-3
- URN
-
urn:nbn:de:bsz:25-freidok-1945356
- Rights
-
Kein Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:00 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
Time of origin
- 2021
Other Objects (12)
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
S125: 10-day decitabine vs. conventional chemotherapy (“3 + 7”) followed by allografting (HSCT) in AML patients ≥60 years: a randomized phase III study of the EORTC Leukemia Group, GIMEMA, CELG, and GMDS-SG
Molekulare Mechanismen der normalen myeloischen Differenzierung und ihrer Störung bei akuten myeloischen Leukämien
Activity of decitabine combined with all-trans retinoic acid in oligoblastic AML: Results from a randomized 2x2 phase II trial (DECIDER)
15-year remission in refractory FLT3-mutated AML attained by sorafenib
15-year remission in refractory FLT3-mutated AML attained by sorafenib
MDS und akute myeloische Leukämie : ein biologisches und therapeutisches Kontinuum
Myelodysplastic syndromes and acute myeloid leukemia : a biological and therapeutic continuum
Impact of TP53 mutation status in elderly AML patients when adding all‐trans retinoic acid or valproic acid to decitabine
Response to daratumumab-retreatment in patients with multiple myeloma
S183: Novel combination immunotherapy for the treatment of relapsed/refractory multiple myeloma: updated phase 1b results for talquetamab (A GPRC5D X CD3 bispecific antibody) in combination with daratumumab
The clinical value of decitabine monotherapy in patients with acute myeloid leukemia
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
S125: 10-day decitabine vs. conventional chemotherapy (“3 + 7”) followed by allografting (HSCT) in AML patients ≥60 years: a randomized phase III study of the EORTC Leukemia Group, GIMEMA, CELG, and GMDS-SG
Molekulare Mechanismen der normalen myeloischen Differenzierung und ihrer Störung bei akuten myeloischen Leukämien
Activity of decitabine combined with all-trans retinoic acid in oligoblastic AML: Results from a randomized 2x2 phase II trial (DECIDER)
15-year remission in refractory FLT3-mutated AML attained by sorafenib
15-year remission in refractory FLT3-mutated AML attained by sorafenib
MDS und akute myeloische Leukämie : ein biologisches und therapeutisches Kontinuum
Myelodysplastic syndromes and acute myeloid leukemia : a biological and therapeutic continuum
Impact of TP53 mutation status in elderly AML patients when adding all‐trans retinoic acid or valproic acid to decitabine
Response to daratumumab-retreatment in patients with multiple myeloma
S183: Novel combination immunotherapy for the treatment of relapsed/refractory multiple myeloma: updated phase 1b results for talquetamab (A GPRC5D X CD3 bispecific antibody) in combination with daratumumab
The clinical value of decitabine monotherapy in patients with acute myeloid leukemia
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
S125: 10-day decitabine vs. conventional chemotherapy (“3 + 7”) followed by allografting (HSCT) in AML patients ≥60 years: a randomized phase III study of the EORTC Leukemia Group, GIMEMA, CELG, and GMDS-SG
Molekulare Mechanismen der normalen myeloischen Differenzierung und ihrer Störung bei akuten myeloischen Leukämien
Activity of decitabine combined with all-trans retinoic acid in oligoblastic AML: Results from a randomized 2x2 phase II trial (DECIDER)
15-year remission in refractory FLT3-mutated AML attained by sorafenib
15-year remission in refractory FLT3-mutated AML attained by sorafenib
MDS und akute myeloische Leukämie : ein biologisches und therapeutisches Kontinuum
Myelodysplastic syndromes and acute myeloid leukemia : a biological and therapeutic continuum
Impact of TP53 mutation status in elderly AML patients when adding all‐trans retinoic acid or valproic acid to decitabine
Response to daratumumab-retreatment in patients with multiple myeloma
S183: Novel combination immunotherapy for the treatment of relapsed/refractory multiple myeloma: updated phase 1b results for talquetamab (A GPRC5D X CD3 bispecific antibody) in combination with daratumumab